Skip to content
sellWeak cluster of 410b5-1 plan

Harpreet S. Dhaliwal sold $935k of PCVX

Chief Technical Ops Officer at Vaxcyte, Inc.. 17,000 shares at an average of $55.00, traded Aug 5, 2026, filed Aug 5, 2026.

Warning score
24
Value
$935k
17,000 shares
Holdings after
76,756
-18% from before
From 52-week low
+88%
low $29.67, close $55.92
From 52-week high
-11%
high $63.04, as of Aug 5, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $935k at market
    +24
  • Share of holdings sold
    Sold 18% of holdings
    +5
  • Cluster
    4 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

PCVXOct 9, 2026 · close 71.38
Since filing Aug 5, 2026: +27.6%SPY +1.3% · excess +26.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001886794-26-000008, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Aug 5, 2026MOption exercise
Common Stock10b5-1
+17,000$24.79$421k93,756Aug 5, 2026
Aug 5, 2026SOpen-market sale
Common Stock10b5-1
-17,000$55.00$935k76,756Aug 5, 2026
Aug 5, 2026MOption exercise
Stock Option (right to buy)derivative10b5-1
-17,000$0.00$028,000Aug 5, 2026

Related signals

Other insiders at Vaxcyte, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
23Weak
PCVXsell 210b5-1
Vaxcyte, Inc.
Elvia Cowan
SVP, Finance & CAO
$1.6M
19,000 shares
-41%
23Weak
PCVXsell 210b5-1
Vaxcyte, Inc.
Jim Wassil
EVP, Chief Scientific Ofc, COO
$1.6M
18,000 shares
-11%
4Weak
PCVXsell 210b5-1
Vaxcyte, Inc.
Jim Wassil
EVP, Chief Scientific Ofc, COO
$128k
2,250 shares
-2%
11Weak
PCVXsell10b5-1
Vaxcyte, Inc.
Jim Wassil
EVP, Chief Scientific Ofc, COO
$164k
2,715 shares
-2%
0Weak
PCVXsell10b5-1
Vaxcyte, Inc.
Jim Wassil
CHIEF OPERATING OFFICER
$212k
3,477 shares
-2%
21Weak
PCVXsell 410b5-1
Vaxcyte, Inc.
Andrew Guggenhime
PRESIDENT AND CFO
$539k
10,000 shares
-9%
10Weak
PCVXsell 410b5-1
Vaxcyte, Inc.
Jim Wassil
CHIEF OPERATING OFFICER
$121k
2,250 shares
-1%
30Weak
PCVXsell 410b5-1
Vaxcyte, Inc.
Grant Pickering
CHIEF EXECUTIVE OFFICER
$1.0M
18,198 shares
-4%
21Weak
PCVXsell 310b5-1
Vaxcyte, Inc.
Andrew Guggenhime
PRESIDENT AND CFO
$573k
10,000 shares
-9%
11Weak
PCVXsell 310b5-1
Vaxcyte, Inc.
Jim Wassil
CHIEF OPERATING OFFICER
$127k
2,250 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Harpreet S. Dhaliwal sold $935k of PCVX | InsiderTell